_ammonium In Intravenous Albumin Preparations

 

The Lancet, Volume 342, Issue 8879, 30 October 1993, Pages 1110-1111 

Copyright © 1993 Published by Elsevier Science Ltd. Letters to the Editor

Ammonium in intravenous albumin preparations R. A. F. M. Chamuleau, G. G. A. Jörning,  F. G. Korse and P. J. Roos  a

Laboratory of Experimental Internal Medicine and Department of Pharmacy, Academic Medical Center, 1105 AZ, Amsterdam, Netherlands

b

Central Laboratory of Netherlands Red Cross Blood Transfusion Service, Amsterdam, Netherlands Available online 21 September 2003. View Abstract

If you do not have a User Name and Password, click the "Register to Purchase" button below to  purchase this article.    

Price: US $ 31.50 

THE LANGET

first exposure to ultra-pure material after many exposures to intermediäre purity product have failed to provoke such a response, raises again the question of altered immunogenicity of ultra-high purity concentrates. S Allard, N Philpott, D H Bevan Department of Haematology, St George's Hospital, London SW17 OQT, UK

1 Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX Inhibitors in haemophiliacs. Ltmcet 1992; 339: 594-98. 2 Peerlinck K, Arnout J, Gilles JG, et al. A higher than expected incidence of factor VIII Inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurised factor VIII concentrate. Thromb Haemostas 1993; 69:115-18.

SlR—Addiego et al report a high frequency of inhibitor development in haemophiliacs treated with low-purity and intermediate-purity factor VIII. Determinante of inhibitor development among haemophiliacs might include age, age at diagnosis, and amount and type of clotting factor VIII infused. Infection with HIV may also affect inhibitor development.1·2 Data from the Italian registry of haemophilia support this hypothesis. So far, 1366 severe (factor VIII <2 lU/dL) haemophilia A patients have been tested for antibodies to HIV and for the presence of inhibitor: inhibitor has been reported in 21% (170/808) of HlV-seronegative haemophiliacs, and in 9% (43/458) of HlV-seropositive haemophiliacs (prevalence odds ratio 2-7, 95% CI 1-8-3-8, p < 0-001). These results show that the presence of HIV infection may be associated with a significantly low frequency of inhibitor to factor VIII because of the immune down-regulation associated with HIV/AID S1·2 Therefore, reports of the evaluation of the frequency of inhibitor should also include Information about HIV serological and clinical Status, especially in the studies that tend to evaluate this aspect of haemophiliacs treated with low and intermediate purity factor VIII concentrates, which certainly in the past have transmitted HIV to some haemophiliacs. Alessandro Ghirardini, Nicola Schinaia, on behalf of the Gruppo Italiano Coagulopatie Congenite Laboratory of Epidemlology Biostatistics, National AIDS Operational Centre, Istltuto Supenore dl Sanita, 00161 Rome, Italy

1 Ragni MV, Bontempo FA, Lewis JH. Disappearance of inhibitor to factor VIII in HlV-infected hemophiliacs with progression to AIDS or severe ARC. Transfusion 1989; 29:447-49. 2 Bray GL, Kroner BL, Arkin S, et al. Loss of high-responder Inhibitors in patients with severe hemophilia A and human immunodeficiency virus type l infection: a report from the multi-center hemophilia cohort study. AmJHematol 1993; 42: 375-79.

SIR—Addiego and colleagues, in their discussion of their results, state that their data can serve to make meaningful comparisons with the frequency of inhibitor develpment in previously untreated patients given only recombinant or monoclonal-antibody-purified concentrates. From a comparison with the results of previous reports on these ultra-pure products, they conclude that the frequency of inhibitor development in patients treated with recombinant factor VIII is lower than in patients with products of lesser purity. To establish the frequency of inhibitor development associated with a particular factor VIII product, one should study patients who were treated solely with that product. Baseline data for inhibitor development on low-purity products should therefore be obtained from patients who used only one low-purity product. Addiego's study is not suitable for future comparisons, since several products were used, both between and within patients.

1110

We reported a frequency of 6-3% in a group of 48 patientsl with severe haemophilia A, analysed in a closely similar way to?| Addiego's patients but exclusively treated with locallyj produced cryoprecipitate.1 Guerois et al2 showed an identical^ incidence (3/48) in patients with severe haemophilia A treated; only with Innovate (high purity, solvent-detergent treated). Addiego and colleagues compare their results with those of * studies on Kogenate and on Recombinate, two recombinant ·. factor VIII preparations, in which frequencies of inhibitor" development are 25%3 and 19%,4 respectively. They fail to'' mention the very short follow-up in these studies. In the Kogenate study, median follow-up was only 9 exposure days in the patients who developed inhibitors, and 7 for those who did · not; in the Recombinate study it was 11 exposure days for both groups combined. Since a median implies that half the events occur before, and half after this period, one may expect almost a doubling of the reported number of inhibitor patients once the follow-up is extended. Obviously, these data on recombinant factor VIII are too preliminary to allow these kind of comparisons. In addition, we have recently demonstrated that a particular intermediate-purity product is clearly immunogenic.5·6 One explanation of the Addiego results could thus be that during the period analysed (1975-85) one or several of their intermediatepurity products was also immunogenic, but that this was not appreciated because this aspect was not systematically studied. We feel that the Statement on the use of these data for future comparisons is erroneous, and that the comparison with ultra-pure products is biased. K Peerlinck, J Vermylen Centre for Molecular and Vascular Biology and Division of Bleeding and Vascular Disorders, University of Leuven, B3000 Leuven, Belgium

F Rosendaal, E Briet Departments of Clinical Epidemiology and Haematology, University of Leiden, Netherlands

Peerlinck K, Rosendaal FR, Vermylen J. Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitate. Blood 1993; 81:3332-35. Guerois C, Rothschild C, Laurian Y, et al. Incidence of inhibitors specific for Factors VIII or IX in severe hemophiliacs A and B only treated with very high purity FVIII or FIX concentrates. Thromb Haemostas 1993; 69: 852. Lusher JM, Arkin S, Abildgaard CF, Schwanz RS, and the Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. N EnglJ Med 1993; 328:453-59. Bray GL, Courter S, Lynes M, Lee M, Gomperts E, and the Recombinate Study Group. Safety, efficacy and inhibitor risk of recombinant factor VIII (RecombinateR) in a cohort of previously untreated patients (PUPs) with severe hemophilia A. Thromb Haemostas<1991; 69:1205. Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemostas 1993; 69: 115-18. Rosendaal FR, Nieuwenhuis HK, van den Berg HM, et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Blood 1993; 81: 2180-86.

Ammonium in intravenous albumin preparations

i ·,

SIR—During our research on the pathogenesis of hepatic · encephalopathy, we unexpectedly found that intravenous -ä albumin preparations contain a significant amount of | ammonium. l In an enzymic assay (glutamate dehydrogenase kit, | Boehringer Mannheim) and with the Blood Ammonia Checker II (Kyoto Daiichi Kagaku, Kyoto, Japan),1 ammonium Vol 342 · October 30,1993